Loading...
•
Dec 31, 2023
Amphastar Q4 2023 Earnings Report
Reported net revenues of $178.1 million and GAAP net income of $36.2 million for the quarter ended December 31, 2023.
Key Takeaways
Amphastar Pharmaceuticals reported a strong fourth quarter with net revenues of $178.1 million and GAAP net income of $36.2 million, driven by glucagon and Primatene MIST® performance and the acquisition of BAQSIMI®.
Net revenues for the fourth quarter were $178.1 million.
GAAP net income for the fourth quarter was $36.2 million, or $0.68 per share.
Adjusted non-GAAP net income for the fourth quarter was $46.9 million, or $0.88 per share.
The company highlighted the submission of its first BLA for Insulin Aspart (AMP-004).
Revenue by Segment
Forward Guidance
Amphastar enters 2024 with strong momentum, driven by glucagon and Primatene MIST performance, the BAQSIMI acquisition, and the Insulin Aspart BLA submission.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...